Live Breaking News & Updates on Coeptis Therapeutics Daily

Stay updated with breaking news from Coeptis therapeutics daily. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Short Interest Up 31.5% in September

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP – Get Free Report) saw a large growth in short interest in the month of September. As of September 15th, there was short interest totalling 58,800 shares, a growth of 31.5% from the August 31st total of 44,700 shares. Approximately 0.4% of the shares of the company are short sold. […] ....

Ionic Capital Management , Coeptis Therapeutics Holdings Inc , Geode Capital Management , Coeptis Therapeutics Holdings , Get Free Report , Director Gene Salkind , Coeptis Therapeutics , Capital Management , Therapeutics Holdings , Coeptis Therapeutics Daily , Nasdaq Coep ,

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Sees Significant Increase in Short Interest

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP – Get Free Report) saw a significant growth in short interest in September. As of September 15th, there was short interest totalling 58,800 shares, a growth of 31.5% from the August 31st total of 44,700 shares. Currently, 0.4% of the company’s stock are sold short. Based on an average trading […] ....

Coeptis Therapeutics Holdings Inc , Geode Capital Management , Securities Exchange Commission , Ionic Capital Management , Coeptis Therapeutics Holdings , Get Free Report , Director Gene Salkind , Exchange Commission , Coeptis Therapeutics , Capital Management , Therapeutics Holdings , Coeptis Therapeutics Daily , Nasdaq Coep ,

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Director Chris Calise Purchases 11,582 Shares of Stock

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP – Get Free Report) Director Chris Calise purchased 11,582 shares of the company’s stock in a transaction that occurred on Wednesday, August 23rd. The shares were purchased at an average cost of $0.94 per share, for a total transaction of $10,887.08. Following the purchase, the director now directly owns 1,464,897 […] ....

United Kingdom , Chris Calise , Cambridge Investment Research Advisors Inc , Coeptis Therapeutics Holdings Inc , Morgan Stanley , Ionic Capital Management , Geode Capital Management , Coeptis Therapeutics Company Profile , Shaolin Capital Management , Coeptis Therapeutics Holdings , Get Free Report , Director Chris Calise , Therapeutics Trading Down , Investment Research Advisors , Coeptis Therapeutics , Capital Management , Therapeutics Holdings , Coeptis Therapeutics Daily , Nasdaq Coep , Insider Trading , Nsider Trades ,

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Director Acquires $10,887.08 in Stock

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP – Get Free Report) Director Chris Calise acquired 11,582 shares of the business’s stock in a transaction that occurred on Wednesday, August 23rd. The shares were purchased at an average price of $0.94 per share, with a total value of $10,887.08. Following the completion of the transaction, the director now […] ....

United Kingdom , Chris Calise , Geode Capital Management , Cambridge Investment Research Advisors Inc , Ionic Capital Management , Securities Exchange Commission , Morgan Stanley , Coeptis Therapeutics Holdings Inc , Coeptis Therapeutics Company Profile , Coeptis Therapeutics Holdings , Get Free Report , Director Chris Calise , Exchange Commission , Therapeutics Holdings , Investment Research Advisors , Coeptis Therapeutics , Capital Management , Coeptis Therapeutics Daily , Nasdaq Coep , Insider Trading , Nsider Trades ,

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Sees Large Decline in Short Interest

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP – Get Free Report) was the recipient of a significant decline in short interest during the month of June. As of June 30th, there was short interest totalling 188,600 shares, a decline of 79.2% from the June 15th total of 905,900 shares. Currently, 1.7% of the company’s stock are sold […] ....

United Kingdom , Ef Hutton Acquisition Co , Cambridge Investment Research Advisors Inc , Coeptis Therapeutics Holdings Inc , Chester Capital Advisors Inc , Coeptis Therapeutics Holdings , Get Free Report , Coeptis Therapeutics , Chester Capital Advisors , Investment Research Advisors , Antara Capital , Therapeutics Holdings , Coeptis Therapeutics Daily ,